Key points are not available for this paper at this time.
YY2 may serve as a promising prognostic biomarker and an innovative therapeutic target for patients with ESCA, regulating cell proliferation, migration, immune microenvironment, and glycolysis.
Gou et al. (Fri,) studied this question.